ADAGIO THERAPEUTICS, INC.

(ADGI)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 30-06-2022
3.280 USD   -0.61%
22/06Adagio Therapeutics, Inc. Kiest Klasse I Bestuurders
CI
21/06Adagio Therapeutics, Inc. Kondigt het ontslag aan van Anand Shah uit de Raad van Bestuur en alle Comités
CI
19/05Adagio Therapeutics verstrekt informatie aan aandeelhouders
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť ADAGIO THERAPEUTICS, INC.
12:31Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board o..
GL
12:30Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board o..
AQ
30/06ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
22/06ADAGIO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
21/06ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
13/06ADAGIO THERAPEUTICS : Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Control..
PU
13/06ADAGIO THERAPEUTICS : ADG20, a half-life–extended monoclonal antibody in development..
PU
19/05ADAGIO THERAPEUTICS : Material Event - Form 8-K
PU
19/05ADAGIO THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
13/05ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
13/05Adagio Therapeutics Reports First Quarter 2022 Financial Results
GL
14/04Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
AQ
31/03ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
30/03ADAGIO THERAPEUTICS : Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to M..
PU
30/03Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to ..
AQ
21/03ADAGIO THERAPEUTICS : AMENDED AND RESTATED EMPLOYMENT AGREEMENT - Form 8-K/A
PU
21/03ADAGIO THERAPEUTICS : AMENDED AND RESTATED EMPLOYMENT AGREEMENT - Form 8-K
PU
21/03ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
21/03ADAGIO THERAPEUTICS, INC. Change in Directors or Principal Officers, Financial Stateme..
AQ
18/03Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
GL
18/03Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
GL
01/03ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
23/02ADAGIO THERAPEUTICS : Announces David Hering Appointed Interim Chief Executive Officer - F..
PU
23/02ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
23/02Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
GL
23/02Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
GL
22/02ADAGIO THERAPEUTICS : Announces CEO Succession Plan - Form 8-K
PU
22/02ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
22/02Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
GL
22/02Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
GL
19/02Adagio Therapeutics Announces CEO Succession Plan
GL
18/02ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
13/01ADAGIO THERAPEUTICS : Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants a..
PU
13/01ADAGIO THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements a..
AQ
12/01Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants ..
GL
12/01Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants ..
GL
06/01Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021ADAGIO THERAPEUTICS : Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against..
PU
2021ADAGIO THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Agains..
AQ
2021ADAGIO THERAPEUTICS : Reports That None of the Mutations Present in SARS-CoV-2 Variant, Om..
PU
2021ADAGIO THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, O..
AQ
2021ADAGIO THERAPEUTICS : Announces Expansion of Management Team and Board of Directors to Sup..
PU
2021ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Discl..
AQ
2021Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Su..
AQ
2021ADAGIO THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
2021ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
2021ADAGIO THERAPEUTICS : Provides Update for ADG20 COVID-19 Antibody Program and Reports Thir..
PU
2021Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Thi..
AQ
2021Adagio Therapeutics to Participate in Upcoming Investor Conferences
GL
2021ADAGIO THERAPEUTICS : Announces New In Vitro Data Highlighting Broad and Potent Neutraliza..
PU
2021ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021ADAGIO THERAPEUTICS : Announces New In Vitro Data Highlighting Broad and Potent Neutraliza..
AQ
2021ADAGIO THERAPEUTICS : ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prol..
PU
2021ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021ADAGIO THERAPEUTICS : Announces New Data Highlighting the Potential of ADG20 for Treatment..
AQ
2021ADAGIO THERAPEUTICS : to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Da..
AQ
2021ADAGIO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2021ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021ADAGIO THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Yea..
AQ